EFFECT OF ACYCLOVIR ON INFECTIOUS-MONONUCLEOSIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EFFECT OF ACYCLOVIR ON INFECTIOUS-MONONUCLEOSIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
复制标题
DOI：
10.1093/infdis/153.2.283
复制
发表时间：
1986-02-01
影响因子：
6.4
通讯作者：
TISELL, A
中科院分区：
文献类型：
--
作者：
ANDERSSON, J;BRITTON, S;TISELL, A
在一项双盲试验中，31例临床和实验室诊断为传染性单核细胞增多症、症状持续时间不超过7天的患者随机或静脉注射阿昔洛韦（10 mg/kg）或安慰剂，间隔8小时，持续7天。记录临床体征和症状，并在治疗前、治疗期间和治疗后6个月内定期评估唾液中的病毒排泄以及血清和唾液中的抗体应答。阿昔洛韦显著（P <0.001），但可逆地抑制EB病毒口咽脱落。然而，两组之间的体液和细胞免疫应答没有差异;病毒潜伏期的发展也没有差异。两组之间的个体临床症状或实验室参数无显著差异（P > 0.05）;然而，当将关于发热持续时间、体重减轻、扁桃体肿胀、咽炎和患者自我评估的数据结合起来时，.01）阿昔洛韦治疗效果明显。
Thirty-one patients with clinical and laboratory diagnoses of infectious mononucleosis who had had symptoms for seven or fewer days were randomized or intravenous treatment with acyclovir (10 mg/kg) or placebo at 8-hr intervals for seven days in a double-blind trial. Clinical signs and symptoms were registered, and excretion of virus in the saliva as well as antibody responses in sera and saliva were assessed before, during, and at regular intervals in the six months after treatment. Acyclovir significantly (P < .001), but reversibly, inhibited oropharyngeal shedding of Epstein-Barr virus. The humoral and cellular immune responses, however, did not differ between the two groups; nor did the development of viral latency. There were no significant (P > .05) differences in individual clinical symptoms or in laboratory parameters between the two groups; however, when data concerning duration of fever, weight loss, tonsillar swelling, pharyngitis, and self-assessment by the patient were combined, a significant (P .ltoreq. .01) effect of treatment with acyclovir was evident.